PharmacovigilanceOfficial

Dutch inspectorate publishes report on January 2026 visit to Crinetics' Amsterdam entity

🇳🇱 IGJ · Fri 06 Nov 2026

IGJ has released an inspection report on Crinetics Pharmaceuticals Europe GmbH in Amsterdam, but the available material does not disclose findings, required measures or the type of inspection.

The Dutch Health and Youth Care Inspectorate (IGJ) has published an inspection report on Crinetics Pharmaceuticals Europe GmbH, following a supervisory visit to the company's Amsterdam location in January 2026.

The item appeared in the inspectorate's supervisory documents section and is dated 6 November 2026. The material available to VigiEye consists only of the document title and a short summary, so the contents of the report itself could not be reviewed.

As a result, it is not known what type of inspection was carried out, whether any deficiencies were identified, or whether the inspectorate asked the company to take improvement measures. Nothing in the available information indicates whether pharmacovigilance, quality or other compliance areas were examined.

Inspection reports of this kind are public documents. Readers who need to know the scope and outcome should consult the full report on the IGJ website.

What it means for your team

  • Regulatory and quality teams with an interest in Crinetics should read the full IGJ report directly, as the findings and any required actions are not summarised in the available information.
  • Pharmacovigilance teams should not assume that any PV deficiencies were or were not found until the inspection type and scope are confirmed from the report.
  • Companies with EU operations in the Netherlands can use published IGJ reports as a reference point for the inspectorate's supervisory approach and inspection readiness.

Official source: IGJ ↗

Article written by VigiEye from the official source (IGJ). AI-assisted; check the source before acting.

More Pharmacovigilance All →